Financials in USD. Standardized financial statements.
A compact view of how Manzo Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2015 | FY 2014 | FY 2004 | FY 2003 |
|---|---|---|---|---|
| Revenue? | $2,014 | $548 | $3.07M | $3.00M |
| Revenue Growth? | +267.5% | -100.0% | +2.2% | 0.0% |
| Cost of Revenue? | $1,221 | $0 | $3.05M | $2.25M |
| Gross Profit? | $793 | $548 | $20,966 | $755,889 |
| Gross Margin? | +39.4% | +100.0% | +0.7% | +25.2% |
| Operating Expenses? | $0 | $246,361 | $3.22M | $4.00M |
| Operating Income? | $793 | -$245,813 | -$3.20M | -$3.25M |
| EBITDA? | $793 | -$448,738 | -$2.85M | -$2.30M |
| Income Before Tax | -$36,244 | -$989,106 | $0 | $0 |
| Income Tax Expense | $0 | $0 | $0 | $0 |
| Net Income? | -$36,244 | -$989,106 | -$4.15M | -$3.95M |
| EPS? | $-0.00 | $-0.00 | $-1.20 | $-1.20 |
| Diluted EPS? | $-0.00 | $-0.00 | $-1.20 | $-1.20 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality